RNS Number : 7643L
Eco Animal Health Group PLC
07 September 2023
 

7 September 2023

ECO Animal Health Group plc ("the Company")

(AIM: EAH)

Result of Annual General Meeting

  

ECO Animal Health Group plc announces that at its Annual General Meeting held earlier today ("AGM") all resolutions proposed to the meeting were duly passed.

 

Proxy votes received in relation to each resolution were as follows:

 

Resolution

For

 

%

 

Discretionary

 

%

Against

 

%

Withheld

01

40,393,039

 

99.996

 

Nil

 

0.000

1,594

 

0.004

Nil

02

37,377,701

 

92.531

 

3,384

 

0.008

3,013,548

 

7.460

Nil

03

40,386,195

 

99.979

 

Nil

 

0.000

8,187

 

0.020

251

04

40,393,039

 

99.996

 

Nil

 

0.000

1,594

 

0.004

Nil

05

40,392,788

 

99.995

 

Nil

 

0.000

1,594

 

0.004

251

06

40,383,756

 

99.973

 

Nil

 

0.000

5,877

 

0.014

5,000

07

40,383,756

 

99.973

 

Nil

 

0.000

5,877

 

0.014

5,000

 

Contacts:

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)

 


020 8447 8899

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Philip Davies

George Tzimas

Sam Butcher

 

 

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Carlo Spingardi

Lydia Zychowska

 

 

020 7597 5970

 

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

 

 

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSSMFDWEDSEIU